



Press Release

Friday, 02 Jan. 2009

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

Strides Arcolab receives USFDA approval for two more products – Takes total Sterile product approvals to 14.

Strides Arcolab Limited (“Strides”) today announced receipt of two ANDA approvals for Sterile Vancomycin HCL USP 500mg and 1g per vial and Sterile Vancomycin HCL USP 5g per vial pharmacy bulk package.

The products are licensed to Akorn-Strides, LLC, which is a Joint Venture that was formed in 2004 by Akorn Inc [NASDAQ: AKRX] and Strides Arcolab Limited [NSE:STAR, BSE: 532531]

Ravi Seth, Chief Executive Officer- International Operations of Strides stated:

“This is a very significant approval for the Strides Akorn partnership and represents a tremendous opportunity in terms of its market size and profitability. Product launch is expected to happen in the first half of 2009”.

Strides Overview

Strides, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a Bangalore, India head quartered global pharmaceutical company. Strides manufactures pharmaceutical formulations in various dosage forms including sterile injectables with dedicated facilities for Penicillin and Penams, Cephalosporins, Oncolytics and lyophilized injectable products. The company also manufactures pharmaceutical formulations in oral dosage forms, including capsules & tablets and Softgel capsules. Strides operates in and has significant presence in Australasia, Africa and India and through a series of strategies is expanding its North American and European growth. The company has series of joint ventures and front-ended operations in major markets and is a majority stakeholder of Ascent Pharmahealth Limited (APH), an ASX listed company. The company also collaborates closely with Global Drug Agencies and US PEPFAR and the UNICEF to supply a range of affordable generic pharmaceutical products used in the treatment of HIV, TB and Malaria.



Strides also has a collaboration agreement with Aspen Pharmacare involving a range of products and territories including a Joint Venture in the oncolytics space in Bangalore. Recently, the JV concluded a significant transaction with GSK to outlicense products for GSK's emerging market strategies in over 95 countries.

Strides has manufacturing facilities in Bangalore, India and overseas facilities in Milan, Warsaw, Singapore and Lagos. The Indian manufacturing facilities are approved by all major regulatory bodies. Strides employs approximately 2,500 people across the globe. Strides also has a marketing presence in over 50 countries.

Additional information is available at the company's website at www.stridesarco.com

For further information, please contact

Mr. Arun Kumar, Group CEO Tel: +91-80-6658 0118	Melissa Arulappan, Corporate Voice/ Weber Shandwick Mobile : +91 98450 22389 Email : melissa@corvoshandwick.co.in
Mr. Ravi Seth, CEO- International Operations Tel: +91 80 6658 0121	Mahesh Nair, Corporate Voice/ Weber Shandwick Mobile : +91 9880376648 Email: maheshn@corvoshandwick.co.in